Follow the Data: Applying PSI as correlates to cancer vaccine patient survival and outcome1

Research Area: Vaccines & immunology research

Development Stage: Prediction

Goal: Identify enhanced polyfunctionality and PSI in after cancer vaccine treatment

[unex_ce_button id="content_10khx0ih9,column_content_611g46odk" button_text_color="#ffffff" button_font="bold" button_font_size="18px" button_width="auto" button_alignment="right" button_text_spacing="1px" button_bg_color="#29acd8" button_padding="15px 30px 15px 30px" button_border_width="0px" button_border_color="#29acd8" button_border_radius="0px" button_text_hover_color="#ffffff" button_text_spacing_hover="1px" button_bg_hover_color="#9cc9d8" button_border_hover_color="#9cc9d8" button_link="" button_link_type="url" button_link_target="_blank" has_container="" in_column="1"]Request a seminar
to follow our data >[/ce_button]

How our single-cell systems are making a difference

Solution: IsoPlexis stratifies higher response rates based on PSI

Finding: Upregulation of Polyfunctional strength ratio (PSR) was correlative to overall survival

Follow the data

GVAX vaccination enhances polyfunctionality and PSI in CD4+ T cells of patients with pancreatic cancer. Polyfunctional CD4+ T cells were evaluated by 24-hour stimulation of anti-CD3/CD28.

An average increase of polyfunctional CD4+ T cells was detected in patients after GVAX treatment. The upregulated PSI of CD4+ T cells by the vaccine was predominated by effector proteins that are associated with antitumor immunity including Granzyme B, IFN-g, MIP-1a and TNF-b. The data was averaged from 5 patients.1

[unex_ce_button id="content_om95el0ye,column_content_g32kkdowi" button_text_color="#424242" button_font="bold" button_font_size="18px" button_width="auto" button_alignment="right" button_text_spacing="1px " button_bg_color="#c9c9c9" button_padding="15px 30px 15px 30px" button_border_width="0px" button_border_color="#c9c9c9" button_border_radius="0px" button_text_hover_color="#424242" button_text_spacing_hover="1px" button_bg_hover_color="#e8e8e8" button_border_hover_color="#e8e8e8" button_link="" button_link_type="url" button_link_target="_blank" has_container="" in_column="1"]Download application note
to learn more >[/ce_button]

IsoPlexis finds critical differences

Single-cell analysis identifies a significant association of CD4+ PSI fold change (post/pre vaccination) with overall survival (OS) of patients with pancreatic cancer after GVAX treatment. Blood was collected from patients before and 10-25 days after GVAX vaccination.

The post- versus pre-vaccination fold-change of PSI of CD4+ T cells was significantly associated with patient OS (P=0.001), indicating a potential of PSI in predicting GVAX vaccine efficacy and prognostic outcomes of patients.1